Catalent, Inc. Stock: price and insider trades · United States

Catalent, Inc. is a leading contract development and manufacturing organization (CDMO) serving pharmaceutical, biotech, and consumer health customers. The company is US-listed on the NYSE/NASDAQ market in the United States (United States), and its investment profile sits squarely in the healthcare outsourcing value chain. Catalent traces its roots to 2007, when it was formed from assets formerly part of Cardinal Health’s pharmaceutical technologies and services platform, and it has since been shaped by a long series of acquisitions and capacity investments. Historically, the company built capabilities around drug-delivery innovation, including softgel technologies, fast-dissolve dosage forms, and cell-line development platforms, giving it a broader technology base than a conventional toll manufacturer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1416083/000141608313000014/catalent-20130630x10k.htm?utm_source=openai))

Operationally, Catalent offers integrated services across product development, fill-finish, multi-modal manufacturing, packaging, and supply-chain support. The company describes itself as a partner that helps customers move programs from early development through launch and lifecycle supply, and it has stated that its teams support more than 100 new product launches each year while working on about 1,500 active customer development programs. Its capabilities span small molecules, oral solids, injectables, biologics, consumer health products, and more specialized platforms such as antibody-drug conjugates and cell therapies. This breadth matters strategically because it allows Catalent to capture work earlier in the product lifecycle and deepen customer relationships over time. ([catalent.com](https://www.catalent.com/about-us/overview/?utm_source=openai))